专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2003068268A3 TREATMENT, DIAGNOSIS AND IMAGING OF DISEASE 审中-公开
公开(公告)号：WO2003068268A3
公开(公告)日：2003-08-21
申请号：PCT/EP2003/001461
申请日：2003-02-13
申请人： BIOINVENT INTERNATIONAL AB , EK, Sara , BORREBAECK, Carl, Arne, Krister , EHINGER, Mats
发明人： EK, Sara , BORREBAECK, Carl, Arne, Krister , EHINGER, Mats
IPC分类号： A61K47/48
摘要： The present invention provides the use of a compound comprising: (i) a binding moiety which selectively binds to a protein listed in Table 1 and (ii) a further moiety in the treatment, imaging, diagnosis or prognosis of mantle cell lymphomas (MCL). Preferably, the binding moiety is an antibody or antigenbinding fragment thereof. Advantageously, the further moiety is a directly or indirectly cytotoxic moiety or a readily detectable moiety. The invention also provides methods of imaging MCL cells, methods of diagnosing or prognosing MCL in an individual and methods of treating an individual with MCL. A further aspect of the present invention provides a method of identifying cells associated with MCL, the method comprising analyzing the pattern of gene expression in a sample of cells to be tested and comparing it to the pattern of gene expression in a sample of known MCL cells. Preferably, the cells to be tested are identified as MCL cells if the expression of one or more genes encoding a protein listed in Table 1 is upregulated compared to normal B-cells.

2. 发明申请

WO2007101676A2 TREATMENT, DIAGNOSIS AND IMAGING OF DISEASE 审中-公开
标题翻译：疾病的治疗，诊断和成像
公开(公告)号：WO2007101676A2
公开(公告)日：2007-09-13
申请号：PCT/EP2007/001962
申请日：2007-03-07
申请人： BIOINVENT INTERNATIONAL AB , BORREBAECK, Carl, Arne, Krister , EK, Sara
发明人： BORREBAECK, Carl, Arne, Krister , EK, Sara
CPC分类号： A61K38/17 , A61K47/6867 , A61K51/1069 , C07K16/3061
摘要： The present invention provides a use a compound comprising a binding moiety which selectively binds to a protein listed in Table 1 in the treatment, imaging, diagnosis or prognosis of mantle cell lymphomas (MCL). Optionally, the compound also comprises a further moiety. Preferably, the binding moiety is an antibody or antigen- binding fragment thereof. Advantageously, the further moiety is a directly or indirectly cytotoxic moiety or a readily detectable moiety. The invention also provides methods of imaging MCL cells, methods of diagnosing or prognosing MCL in an individual and methods of treating an individual with MCL A further aspect of the present invention provides a method of identifying cells associated with MCL, the method comprising analysing the pattern of gene expression in a sample of cells to be tested and comparing it to the pattern of gene expression in a sample of known MCL cells. Preferably, the cells to be tested are identified as MCL cells if the expression of one or more genes encoding a protein listed in Table 1 is upregulated compared to normal B -cells.
摘要翻译：本发明提供使用包含结合部分的化合物，所述结合部分选择性地结合表1中列出的蛋白质在外套细胞淋巴瘤（MCL）的治疗，成像，诊断或预后中。任选地，化合物还包含另外的部分。优选地，结合部分是抗体或其抗原结合片段。有利地，另外的部分是直接或间接的细胞毒性部分或易于检测的部分。本发明还提供了成像MCL细胞的方法，个体中MCL的诊断或预后的方法以及用MCL治疗个体的方法。本发明的另一方面提供了鉴定与MCL相关的细胞的方法，该方法包括分析模式的基因表达在待测试的细胞样品中，并将其与已知MCL细胞的样品中的基因表达模式进行比较。如果与正常的B细胞相比，如果编码表1中列出的蛋白质的一种或多种基因的表达上调，则优选将待测试的细胞鉴定为MCL细胞。

3. 发明申请

WO2003068268A2 TREATMENT, DIAGNOSIS AND IMAGING OF DISEASE 审中-公开
标题翻译：疾病的治疗，诊断和成像
公开(公告)号：WO2003068268A2
公开(公告)日：2003-08-21
申请号：PCT/EP2003/001461
申请日：2003-02-13
申请人： BIOINVENT INTERNATIONAL AB , EK, Sara , BORREBAECK, Carl, Arne, Krister , EHINGER, Mats
发明人： EK, Sara , BORREBAECK, Carl, Arne, Krister , EHINGER, Mats
IPC分类号： A61K51/00
CPC分类号： A61K47/50
摘要： The present invention provides the use of a compound comprising: (i) a binding moiety which selectively binds to a protein listed in Table 1 and (ii) a further moiety in the treatment, imaging, diagnosis or prognosis of mantle cell lymphomas (MCL). Preferably, the binding moiety is an antibody or antigenbinding fragment thereof. Advantageously, the further moiety is a directly or indirectly cytotoxic moiety or a readily detectable moiety. The invention also provides methods of imaging MCL cells, methods of diagnosing or prognosing MCL in an individual and methods of treating an individual with MCL. A further aspect of the present invention provides a method of identifying cells associated with MCL, the method comprising analyzing the pattern of gene expression in a sample of cells to be tested and comparing it to the pattern of gene expression in a sample of known MCL cells. Preferably, the cells to be tested are identified as MCL cells if the expression of one or more genes encoding a protein listed in Table 1 is upregulated compared to normal B-cells.
摘要翻译：本发明提供了一种化合物的用途，所述化合物包括：选择性结合表1所列蛋白质的结合部分，以及外套细胞淋巴瘤MCL的治疗，成像，诊断或预后的另一部分。优选地，结合部分是抗体或其抗原结合片段。有利地，另外的部分是直接或间接的细胞毒性部分或易于检测的部分。本发明还提供了成像MCL细胞的方法，个体中诊断或预测MCL的方法和用MCL治疗个体的方法。本发明的另一方面提供了鉴定与MCL相关的细胞的方法，所述方法包括分析待测试细胞样品中基因表达的模式，并将其与已知MCL细胞样品中的基因表达模式进行比较。如果与正常B细胞相比，如果编码表1中列出的蛋白质的一种或多种基因的表达上调，则优选将待测试的细胞鉴定为MCL细胞。

4. 发明申请

WO2010023458A1 METHOD OF DIAGNOSING OR PROGNOSING EPITHELIAL OVARIAN CANCER 审中-公开
标题翻译：诊断或预防上皮癌的方法
公开(公告)号：WO2010023458A1
公开(公告)日：2010-03-04
申请号：PCT/GB2009/002098
申请日：2009-09-01
申请人： IMMUNOVIA AB , BORREBAECK, Carl, Arne, Krister , EK, Sara, Charlotte, Andersson , BRENNAN, Donal, John
发明人： BORREBAECK, Carl, Arne, Krister , EK, Sara, Charlotte, Andersson , BRENNAN, Donal, John
IPC分类号： C12Q1/68 , G01N33/574
CPC分类号： G01N33/57449 , C12Q1/6886 , C12Q2600/118 , C12Q2600/158 , G01N2500/00 , G01N2800/56
摘要： The present invention provides a binding moiety which selectively binds to Sox11 protein and/or mRNA for imaging, diagnosis or prognosis of epithelial ovarian cancer (EOC). Optionally, the moiety is an antibody or antigen-binding fragment thereof. Advantageously, moiety comprises a further, readily detectable moiety. The invention also provides methods of imaging EOC cells as well as methods of diagnosing or prognosing EOC in an individual. A further aspect of the present invention provides a method of identifying cells associated with EOC, the method comprising analysing the pattern of gene expression in a sample of cells to be tested and comparing it to the pattern of gene expression in a sample of known lymphomas cells. Preferably, the cells to be tested are identified as EOC cells if the expression of Sox11 is up-regulated compared to normal B-cells. Preferably EOC cells are identified as improved recurrence-free survival-associated if expression of Sox11 is up-regulated compared with non-cancerous epithelial ovarian cells. Preferably, EOC cells are identified as diminished recurrence-free survival-associated if expression of Sox11 is similar to, or down-regulated, compared with non-cancerous epithelial ovarian cells.
摘要翻译：本发明提供了选择性结合Sox11蛋白和/或mRNA用于成像，诊断或预后的上皮性卵巢癌（EOC）的结合部分。任选地，该部分是抗体或其抗原结合片段。有利地，部分包含另外易于检测的部分。本发明还提供对EOC细胞进行成像的方法以及在个体中诊断或预测EOC的方法。本发明的另一方面提供了鉴定与EOC相关的细胞的方法，所述方法包括分析待测试细胞样品中基因表达的模式，并将其与已知淋巴瘤细胞样品中基因表达的模式进行比较。如果与正常B细胞相比，如果Sox11的表达被上调，则待测试的细胞被鉴定为EOC细胞。如果与非癌性上皮性卵巢细胞相比，如果Sox11的表达上调，则优选EOC细胞被鉴定为改善的无复发存活相关性。优选地，与非癌性上皮性卵巢细胞相比，如果Sox11的表达与非癌性上皮性卵巢细胞相似或下调，则EOC细胞被鉴定为减少的无复发存活相关。

5. 发明申请

WO2008139169A1 SOX11 EXPRESSION IN MALIGNANT LYMPHOMAS 审中-公开
标题翻译：恶性淋巴瘤中的SOX11表达
公开(公告)号：WO2008139169A1
公开(公告)日：2008-11-20
申请号：PCT/GB2008/001625
申请日：2008-05-12
申请人： IMMUNOVIA AB , BORREBAECK, Carl, Arne, Krister , EK, Sara
发明人： BORREBAECK, Carl, Arne, Krister , EK, Sara
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , A61K51/1069 , C07K16/00 , C07K16/18 , C12Q2600/118 , C12Q2600/158 , G01N33/57496 , G01N2500/20 , G01N2800/52
摘要： The present invention provides a binding moiety which selectively binds to Sox1 1 protein and/or mRNA for imaging, diagnosis or prognosis of lymphomas, such as mantle cell lymphomas (MCL) and diffuse large B-cell lymphoma (DLBCL). Optionally, the moiety is an antibody or antigen-binding fragment thereof. Advantageously, moiety comprises a further, readily detectable moiety. The invention also provides methods of imaging lymphomas cells as well as methods of diagnosing or prognosing lymphomas in an individual. A further aspect of the present invention provides a method of identifying cells associated with lymphomas, the method comprising analysing the pattern of gene expression in a sample of cells to be tested and comparing it to the pattern of gene expression in a sample of known lymphomas cells. Preferably, the cells to be tested are identified as lymphoma cells if the expression of Sox11 is upregulated compared to normal B-cells.
摘要翻译：本发明提供了结合部分，其选择性结合Sox1蛋白和/或mRNA用于淋巴瘤（例如外套细胞淋巴瘤（MCL）和弥漫性大B细胞淋巴瘤（DLBCL））的成像，诊断或预后。任选地，该部分是抗体或其抗原结合片段。有利地，部分包含另外易于检测的部分。本发明还提供了对淋巴瘤细胞进行成像的方法以及诊断或预测个体中淋巴瘤的方法。本发明的另一方面提供了鉴定与淋巴瘤相关的细胞的方法，所述方法包括分析待测试细胞样品中基因表达的模式，并将其与已知淋巴瘤细胞样品中的基因表达模式进行比较。如果与正常B细胞相比，如果Sox11的表达上调，则优选将待测试的细胞识别为淋巴瘤细胞。

6. 发明申请

WO2003097834A3 A METHOD FOR IN VITRO MOLECULAR EVOLUTION OF PROTEIN FUNCTION 审中-公开
公开(公告)号：WO2003097834A3
公开(公告)日：2003-11-27
申请号：PCT/GB2003/002102
申请日：2003-05-16
申请人： ALLIGATOR BIOSCIENCE AB , THOMAS, Philip, John, Duval , FUREBRING, Christina , CARLSSON, Roland , BORREBAECK, Carl, Arne, Krister , MALMBORG, Hager, Ann-Christin
发明人： FUREBRING, Christina , CARLSSON, Roland , BORREBAECK, Carl, Arne, Krister , MALMBORG, Hager, Ann-Christin
IPC分类号： C12N15/10
摘要： A method for in vitro molecular evolution of protein function The invention provides a method for generating a polynucleotide sequence or population of sequences from parent single-stranded polynucleotide sequences encoding one or more protein motifs, comprising the steps of (a) providing a first population of single-stranded polynucleotide molecules and a second population of single-stranded polynucleotide molecules, the first and second populations together constituting plus and minus strands of parent polynucleotide sequences, (b) carrying out a reaction for digesting the first and second populations of single-stranded polynucleotide molecules with an exonuclease to generate corresponding populations of single-stranded polynucleotide fragments, (c) contacting said fragments generated from the plus strands with fragments generated from the minus strands and optionally, adding primer sequences that anneal to the 3'and 5'ends of at least one of the parent polynucleotides under annealing conditions, and (d) amplifying the fragments that anneal to each other to generate at least one polynucleotide sequence encoding one or more protein motifs having altered characteristics as compared to the one or more protein motifs encoded by said parent polynucleotides, wherein, in step (b), at least one parameter of the reaction used for digestion of the first population of single-stranded polynucleotide molecules is different from the equivalent parameter(s) used in the reaction for digestion of the second population of single-stranded polynucleotide molecules. Preferably, the reaction parameter is selected from exonuclease type, exonuclease concentration, reaction volume, duration of the digestion reaction, temperature of the reaction mixture, pH of the reaction mixture, length of parent single-stranded polynucleotide sequences, amount of single-stranded polynucleotide molecules and buffer composition of the reaction mixture.

7. 发明申请

WO2009068857A1 DIAGNOSTIC METHODS AND ARRAYS FOR USE IN THE SAME 审中-公开
标题翻译：诊断方法及其使用的阵列
公开(公告)号：WO2009068857A1
公开(公告)日：2009-06-04
申请号：PCT/GB2008/003922
申请日：2008-11-24
申请人： IMMUNOVIA AB , BORREBAECK, Carl, Arne, Krister , WINGREN, Lars, Bertil, Christer
发明人： BORREBAECK, Carl, Arne, Krister , WINGREN, Lars, Bertil, Christer
IPC分类号： G01N33/574
CPC分类号： G01N33/57415 , G01N33/6863 , G01N33/6869 , G01N2333/5409
摘要： The present invention provides a method for determining the presence of breast cancer cells in an individual comprising the steps of (a) providing a serum or plasma sample to be tested and (b) determining a protein signature of the test sample by measuring the presence and/or amount in the test sample of two or more proteins selected from the group defined in Table 1 a or 1 b, wherein the presence and/or amount in the test sample of the two or more proteins selected from the group defined in Table 1a or 1 b is indicative of the presence of breast cancer cells. In a preferred embodiment, the two or more proteins include IL-5 and/or MCP-3. Also provided are arrays and diagnostic kits for use in the methods of the invention.
摘要翻译：本发明提供了确定个体中乳腺癌细胞存在的方法，其包括以下步骤：（a）提供待测试的血清或血浆样品，和（b）通过测量所述测试样品的存在和/ /或选自表1a或1b中定义的组的两种或更多种蛋白质的测试样品中的量，其中选自表1a中定义的组中的两种或更多种蛋白质的测试样品中的存在和/或量或1b表示乳腺癌细胞的存在。在优选的实施方案中，两种或更多种蛋白质包括IL-5和/或MCP-3。还提供了用于本发明方法的阵列和诊断试剂盒。

8. 发明申请

WO2011128642A1 COMPOISITONS COMPRISING POLYGLUTAMIC ACID NANOPARTICLES AND POLYPEPTIDES SUCH AS CD40 AGONISTS 审中-公开
标题翻译：包含聚氨基酸纳米颗粒和多肽的组合物如CD40激动剂
公开(公告)号：WO2011128642A1
公开(公告)日：2011-10-20
申请号：PCT/GB2011/000577
申请日：2011-04-13
申请人： ALLIGATOR BIOSCIENCE AB , SMITH, Stephen, Edward , BORREBAECK, Carl, Arne, Krister , BROOS, Sissela, Rachel, Linn , ELLMARK, Peter, Bo, Joakim , LINDSTEDT, Malin, Marie
发明人： BORREBAECK, Carl, Arne, Krister , BROOS, Sissela, Rachel, Linn , ELLMARK, Peter, Bo, Joakim , LINDSTEDT, Malin, Marie
IPC分类号： A61K9/14 , A61K39/39 , A61K39/395 , A61K47/34 , A61K9/00
CPC分类号： A61K39/39 , A61K9/0019 , A61K9/146 , A61K9/5146 , A61K2039/55516 , A61K2039/55555
摘要： The present invention provides pharmaceutical compositions comprising an immunostimulatory polypeptide and polyglutamic acid (PGA) nanoparticles, formulated in a pharmaceutically acceptable diluent, carrier or excipient. Such compositions have utility in stimulating the immune system in subjects, with the components capable of interacting synergistically. The invention further provides uses of the compositions of the invention, for example in the treatment of cancer, and kit and components for use in the same.
摘要翻译：本发明提供包含免疫刺激多肽和聚谷氨酸（PGA）纳米颗粒的药物组合物，其配制在药学上可接受的稀释剂，载体或赋形剂中。这些组合物可有效地刺激受试者的免疫系统，其中组分能够协同相互作用。本发明进一步提供本发明组合物的用途，例如用于治疗癌症，以及用于其中的试剂盒和组分。

9. 发明申请

WO2008117067A9 PROTEIN SIGNATURE/MARKERS FOR THE DETECTION OF ADRENOCARCINOMA 审中-公开
公开(公告)号：WO2008117067A9
公开(公告)日：2008-10-02
申请号：PCT/GB2008/001090
申请日：2008-03-25
申请人： BORREBAECK, Carl, Arne, Krister , WINGREN, Lars, Bertil, Christer
发明人： BORREBAECK, Carl, Arne, Krister , WINGREN, Lars, Bertil, Christer
IPC分类号： G01N33/574
摘要： The present invention provides a method for determining the presence of pancreatic adenocarcinoma in an individual and/or for determining the survival time of an individual afflicted with pancreatic adenocarcinoma comprising the steps of: (a) providing a serum or plasma sample to be tested; and (b) determining a protein signature of the test sample by measuring the presence and/or amount in the test sample of one or more selected proteins; wherein the presence and/or amount in the test sample of one or more proteins selected from the group defined in Table 1 is indicative of the presence of pancreatic adenocarcinoma. The invention also provides an array and a kit suitable for use in the methods of the invention.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式